TL;DR
- On 6 October 2026 the National Medical Commission (NMC) issued guidelines on ethical advertising and public communication for doctors and hospitals. They apply with immediate effect.
- Digital, social, search, influencer and AI-generated promotion now counts as advertising when the content, or the way it is distributed, is promotional.
- Patient testimonials, before-and-after photos, superlatives, discounts, doctor endorsements of products and per-patient agency fees are now unethical marketing practices. Patient consent does not bring them back.
- Educational content, factual hospital information, doctor directories and published fees are still allowed. SEO is not banned.
- Every electronic post by a doctor needs a disclosure line with name, qualifications, registration status and registration number. Permitted AI content needs a visible AI label.
Introduction to the New Healthcare Marketing
India’s healthcare landscape has got a big shock with the public notice issued by EMRC board of the NMC. The NMC Advertising Guidelines 2026 has changed how the healthcare industry promotes itself. The biggest trust factors that used to empower the marketing throughout their entire budget is now considered an unethical practice. Testimonials, before-after sessions, even when consented by the patient is an immoral practice as from now. The National Medical Commission (NMC) issued these guidelines on October 06, 2026, and this will have a major effect on the digital marketing industry as well.
In this read, you can understand what these guidelines mean for you if you work in healthcare marketing in 2026 or have been in the healthcare industry.
What are the NMC advertising guidelines 2026?
On October 06, 2026, the Ethics and Medical Registration Board (EMRB) of the NMC issued public Notice No. R-13013/01/224-Ethics: The Guidelines on Ethical Advertising and Public Communication by Hospitals/Medical Institutions and Registered Medical Practitioners (RMP).
The notice issued guidelines for healthcare digital marketing for RMP and medical institutions that referred to advertising on social media, website, blog posts, e-mandates, and influencer campaigns. The notice clearly declared practices like testimonials, patient data discretion, and success stories, as unethical marketing practices.
The public notice was framed after a supreme Court Civil Writ Petition No, 1160/2023 and the Indian Medical Council (Professional Conduct, Etiquette, and Ethics) Regulations, 2002. Let’s understand why this happened and how it’s going to shift the marketing landscape.
Long Story Short: The Supreme Court Case Against NMC
Dr. Annirudha Malpani, a medical practitioner, noticed a loophole in the Indian Medical Council Regulations, 2002. As hospitals and clinics were registered as corporate bodies, they were out of reach for the regulations. They fabricated success stories & made fake testimonials, trying to lure patients.
Dr. Annirudha filed a Public Interest Litigation (PIL) in September 2023, with their advocate Mohini Priya asking the honorable Supreme Court to take strict actions against it through a Writ of Mandamus (A judicial Command).
The Supreme Court issued notice to the NMC asking why they failed to curb the unethical practices and called it fear-based marketing. On September 27, 2026, the NMC was ordered to revise the guidelines in under 2 weeks. This resulted in the public notice issued on October 06, 2026.
Find Supreme Court Case Details here: https://www.sci.gov.in/
| Services | Daily Orders |
|---|---|
| Case Type | Writ Petition (Civil) |
| Case no. | 1160 |
| Year | 2023 |
Whom Did the NMC Advertising Guidelines 2026 Refer to?
The Registered Medical Practitioners, Medical/Hospital Institutions are referred to in the document directly. While the people outside NMC’s reach are also addressed in the public notice as well. Here’s the complete list of the people who should care about the notice:
- Registered Medical Practitioners (RMPs): doctors on the National Medical Register or a State Medical Register. State Medical Councils discipline them.
- Hospitals and medical institutions: the guidelines are read with the Clinical Establishments Act or the relevant state act. Where the two conflict, the state law wins (para 4.3), and penalties for institutions follow that act.
- Agencies, influencers and platforms: not regulated directly. But para 4.4 says publishing through them does not absolve a doctor or hospital of content they authorised, commissioned, sponsored, adopted or knowingly permitted. Platforms that list doctors have their own duty on paid ranking (para 9.4).
- Outside the NMC’s reach: dentists answer to the Dental Council of India, AYUSH practitioners to their own councils, and non-doctor wellness influencers to consumer-protection and advertising-standards regimes. Whether the rules reach marketing aimed at patients abroad is unsettled (see the grey areas below).
Important Shifts that Change Healthcare Marketing
| Shift | Where | What it means for marketers |
|---|---|---|
| Digital promotion is explicitly covered | 3.2, 3.5 | Promotional communication across social media, search, sponsored posts, influencer marketing, WhatsApp, podcasts and websites falls within the advertising framework. |
| Patient testimonials and promotional reviews are restricted | Explanation V, 6.2 | Doctors must not request or share patient testimonials, recommendations, endorsements or reviews for professional promotion on social media. Consent does not make otherwise prohibited promotional content permissible. |
| Electronic posts require doctor identification | Explanations III and IV | Each electronic-media post by a doctor must carry the prescribed name, qualifications, registration status and SMR/NMR number. Hospitals must provide the corresponding details for every doctor they name. |
| AI-generated promotion faces restrictions | 7.2 | AI-generated promotional campaigns for commercial interest are prohibited under the guidelines. AI-generated content must carry the prescribed source identification. Labelling does not override other restrictions. |
| Third-party publishing does not remove responsibility | 4.4, 8.1(vii), 8.1(viii) | Doctors and institutions remain accountable for covered promotional content they authorise or knowingly permit. Referral commissions and prohibited patient-linked payments require particular scrutiny; ordinary agency fees should be assessed separately. |
| Disciplinary consequences are graduated | 10.1 | Consequences may range from warnings and ethics training to removal from the medical register for one to three years, depending on the applicable disciplinary framework. |
From disciplinary consequences to digital promotions, the decisions fall in a specific word: “Explicit Prohibition”, however, the prohibitions and exemptions are particularly defined. According to the Chapter III of the NMC Advertising Guidelines 2026, here are the exact prohibitions listed with their accurate interpretations:
NMC 2026 Advertising Guidelines: Explicit Restrictions and Digital Marketing Examples
| Para | What it prohibits | A digital-marketing example that may breach the guidelines |
|---|---|---|
| 8.1(i) | Creating unnecessary demand for medical services, promoting unnecessary diagnostic investigations, or using fear-based marketing to solicit patients. | A fear-based hook about a “silent blockage” used to push an unnecessary full-body screening package. |
| 8.1(ii) | Soliciting patients, self-promotion, engaging third parties to market medical services, or permitting one’s name, image or other identifying attributes to be used for prohibited promotion. | A paid promotional campaign urging people to “Book your consultation with Dr X today” to solicit patients for an individual doctor’s practice. |
| 8.1(iii) | Making prohibited or misleading claims about success rates, patient numbers, professional achievements, or superiority, including claims such as “Best,” “No. 1,” “100% success,” “painless” or “miracle cure.” | A homepage counter stating “10,000+ successful surgeries” as a promotional claim of patient volume and treatment success. |
| 8.1(iv) | Endorsing or recommending drugs, medicines, remedies, medical devices, diagnostic products, health products or other commercial products in connection with one’s professional identity, whether paid or unpaid. | A doctor-fronted Instagram Reel endorsing a supplement or skincare product for commercial promotion. |
| 8.1(v) | Using patient case histories, surgical results, before-and-after photographs, celebrity patients or success stories for prohibited promotional purposes, subject to expressly permitted scientific or educational uses and applicable safeguards. | An Instagram carousel displaying patient treatment results or before-and-after images to attract prospective patients. |
| 8.1(vi) | Creating unrealistic expectations, concealing or misrepresenting treatment risks, or promoting unproven therapies and treatments without adequately established scientific basis, safety or efficacy. | An advertisement promising “Back to normal in 24 hours” without adequate substantiation or appropriate disclosure of material risks. |
| 8.1(vii) | Offering or receiving commissions, rebates, bonuses, referral fees, lead-generation fees or other considerations connected with referring, recommending or procuring patients, specimens or materials for medical services. | Paying an agency or aggregator on a cost-per-lead basis where the payment is linked to procuring or referring individual patients. |
| 8.1(viii) | Remuneration arrangements involving advertising agencies, digital marketing agencies, influencers or online platforms that are linked to the procurement or referral of individual patients. | A marketing contract that combines a retainer with an additional payment for every patient referred or procured by the agency. |
| 8.1(ix) | Making comparative or superiority claims that cannot be objectively substantiated in accordance with the applicable requirements, including misleading claims about rankings, awards or professional standing. | Promoting a hospital as “The Most Trusted Hospital in the City” based on an unverifiable ranking or a purchased award presented as independent recognition. |
| 8.1(x) | Using discounts, limited-period offers, contests, coupons, cashbacks, gifts or free procedures in ways prohibited by the guidelines, including inducements likely to encourage unnecessary consultations, investigations or treatment, or to solicit patients. | A “Flat 30% Off This Diwali” treatment campaign or “Free Consultation This Week” offer used as an inducement to solicit patients. |
| 8.1(xi) | Using or permitting celebrity, influencer, patient, staff or other third-party endorsements and recommendations to achieve indirectly what is prohibited directly. | An influencer Reel stating “I got my treatment here, and you should too” as part of a clinic’s promotional campaign. |
| 8.1(xii) | Creating or purchasing fake followers, likes, reviews, ratings, testimonials, comments or views, or manipulating search rankings, visibility or algorithms to mislead the public about professional standing. | Buying followers or fake reviews, or using deceptive link schemes to manipulate search visibility and create a misleading impression of reputation. |
Note: These examples illustrate practices that may breach paragraph 8.1. Their compliance depends on the precise circumstances and the applicable exceptions or conditions in the guidelines. Paragraph 8.1 should also be read alongside the relevant provisions on permitted communications and the separate requirements for hospitals and medical institutions.
How the NMC 2026 Guidelines Affect Healthcare Digital Marketing and How to Do It The New Way?
The NMC guidelines dated 6 October 2026 do not eliminate healthcare communication; they draw a sharper line between factual information and promotion. Individual registered medical practitioners (RMPs) face restrictions on self-promotion and patient solicitation, while hospitals may publish factual, objective and verifiable institutional information within the guidelines.
SEO and Websites
Educational articles, technical SEO and accurate service pages can continue. Paragraph 8.1(xii) targets fake engagement and manipulative ranking practices, not legitimate visibility. Audit titles, headings, metadata and structured data for unsupported claims such as “best,” “No. 1,” “painless” or “guaranteed.” Avoid using testimonials and treatment results as promotional proof.
Reviews and Paid Advertising
Take a conservative approach to patient reviews. Do not request promotional reviews in a doctor’s name, incentivise or gate reviews, or republish them as marketing testimonials. The treatment of unprompted reviews on third-party platforms is not fully clarified, so seek legal advice before running review-generation campaigns.
For individual doctors, avoid paid campaigns that promote their practice or solicit patients. Hospitals can communicate factual information about departments, facilities, accreditations, emergency services and fees, but should avoid offers, superiority claims, outcome promises and promotional portrayals of individual doctors.
Social Media, Messaging and AI
Every electronic post by a doctor must include the prescribed name, qualifications, registration status and SMR/NMR number. Retire promotional testimonials, before-and-after images, celebrity-patient stories, product endorsements and influencer treatment promotions.
Commercial AI-generated promotional campaigns are prohibited. AI-generated content must carry the prescribed visible source mark where required; labelling does not make otherwise prohibited promotion compliant.
Avoid mass promotional WhatsApp, SMS and email broadcasts or unsolicited package offers. Prioritise appropriate patient-care updates and service communications, with consent and data-protection safeguards.
Listings and Agency Contracts
Doctor-listing platforms must prohibit paid ranking of doctors. Referral fees, lead-generation fees and agency or platform payments tied to individual patients are high risk. The separate restriction on engaging third parties to market a doctor’s services may also affect agency arrangements. A fixed retainer avoids per-patient remuneration but does not automatically resolve this separate issue. Obtain legal advice before finalising contracts.
Where Budgets Should Shift
Prioritise educational content, technical SEO, accurate institutional pages and clear content-approval processes. These are practical compliance recommendations, not a substitute for legal advice on a specific campaign.
Other Laws That Sit Alongside the NMC Guidelines
The NMC guidelines operate alongside other laws and advertising standards. The following distinctions matter: some laws are expressly referenced in the notice, while others apply independently.
| Law or code | Why it matters | Status |
|---|---|---|
| Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002 | Paragraph 4.2 requires the guidelines to be read alongside these regulations, including provisions on signboards and letterheads. | Named in the notice |
| National Medical Commission Act, 2019 | Governs medical registration and the appeals process under sections 30(3) and 30(4). | Named in the notice |
| Clinical Establishments Act or applicable State Act | Governs hospital-level penalties. Applicable legislation takes precedence in the event of an irreconcilable conflict with the guidelines. | Named in the notice |
| Information Technology Act, 2000 and Digital Personal Data Protection Act, 2023 and Rules, 2025 | Relevant to personal data used in advertising, subject to the provisions in force at the relevant time. The DPDP framework has phased commencement. | Named in the notice |
| Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 | Independently restricts specified drug advertisements and remedy claims. | Additional applicable law |
| ASCI Code | Advertising self-regulation. ASCI’s 2025–26 reporting indicates that digital media accounted for 97.3% of advertisements scrutinised for potential violations. Its report also records 274 cases involving products violating the Drugs and Magic Remedies Act. | Self-regulatory code |
| Consumer Protection Act, 2019 and CCPA advertising and endorsement guidelines | Relevant to misleading claims, endorsements and advertiser liability. | Additional applicable law |
| PCPNDT Act and Assisted Reproductive Technology (Regulation) Act, 2021 | Impose specific advertising restrictions relating to sex selection, prenatal sex determination and specified ART-related activities. | Additional applicable laws |
| Surrogacy (Regulation) Act, 2021 | Prohibits specified forms of advertising promoting commercial surrogacy or soliciting women to act as surrogate mothers. | Additional applicable law |
Penalties and Enforcement: What the Guidelines Say
Paragraph 10.1 provides a graded disciplinary framework. The State Medical Council may contemplate the following measures; they are not automatic outcomes in every case.
| Stage | Action contemplated |
|---|---|
| First violation | Warning and mandatory ethics training |
| Second violation | Censure and monetary penalty |
| Third violation | Suspension of registration for three to six months |
| Serious violation | Suspension for six to twelve months |
| Repeated violations | Removal from the medical register for one to three years |
Process and Appeals
Paragraphs 10.2 and 10.3 require a show-cause notice, an opportunity for the doctor to respond, and a reasoned order explaining the findings and penalty.
Under paragraphs 11.1 and 11.4, an appeal may be filed before the Ethics and Medical Registration Board (EMRB) within 60 days under section 30(3) of the NMC Act. A second appeal under section 30(4) must be filed within 60 days of communication of the first appeal decision.
Hospitals are dealt with under the applicable Clinical Establishments Act and rules or State Act. Under paragraph 11.5, a doctor who authorised, participated in or endorsed prohibited communication may be examined separately. A medical director’s approval can therefore create individual disciplinary exposure, although liability is not automatic.
A framework, not a tariff: The notice says disciplinary action “may be contemplated”. The facts, severity and applicable provisions matter; the stages should not be treated as an automatic sequence.
What Enforcement May Look Like
The notice establishes disciplinary consequences but does not set out a dedicated monitoring system for every platform, agency or AI-generated advertisement. ASCI separately uses proactive monitoring, so enforcement should not be described as exclusively complaint-driven.
Platforms have specific obligations under paragraph 9.4 concerning paid doctor rankings and transparency. Agencies and healthcare providers may also face obligations under other applicable laws.
The NMC’s guidelines took effect on 6 October 2026. They do not expressly direct the deletion of every pre-existing post or set out a separate grandfathering rule. However, older content that remains accessible should be audited for ongoing compliance. Correcting problematic content and maintaining a dated change log are prudent risk-management measures.
These are compliance recommendations, not guarantees about how a regulator will approach a particular case.
What to Watch Next
- NMC clarifications: Paragraph 12 permits further clarifications, advisories, standard operating procedures and procedural instructions.
- Supreme Court proceedings: Monitor developments in Writ Petition (Civil) No. 1160/2023, referenced in the notice.
- Platform and AI requirements: Watch for further directions affecting listing platforms, agencies and AI-generated advertising.
- Hospital regulation: Monitor how the guidelines interact with applicable State Clinical Establishments laws.
- Advertising enforcement: Track ASCI and consumer-protection authorities’ actions involving healthcare claims.
Update log: First published 14 October 2026.
